StudyRareStudyRare

Heritable pulmonary arterial hypertension

Log in to star

Last updated Nov 3, 2026

Log in to add personal notes on this page.

A 30-year-old woman presents with progressive dyspnea on exertion, exertional syncope, and lower-extremity edema. Right heart catheterization confirms pre-capillary pulmonary hypertension (mPAP 45 mmHg, PVR 8 WU, PAWP 10 mmHg). Family history reveals a paternal uncle who died young of "heart failure" and a paternal cousin diagnosed with pulmonary hypertension in her 20s.

AD with markedly reduced penetrance (~14-20% lifetime in carriers overall, but sex-stratified ≈ 14% in males vs. ≈ 42% in females; female:male affected ≈ 2-4:1). Most cases are BMPR2 (bone morphogenetic protein receptor type 2), through loss-of-function variants in a BMP signaling pathway of the pulmonary endothelium.

GeneMechanismNotes
BMPR2LOF / haploinsufficiency of BMP receptor type 2 in pulmonary endothelium; some variants dominant negative~70-80% of heritable PAH; ~10-20% of "idiopathic" PAH
ACVRL1 (ALK1)TGF-β/BMP signalingOverlap with HHT (HHT-PAH overlap syndrome)
ENGTGF-β co-receptorAlso causes HHT type 1
GDF2BMP9 ligandMore recent gene
KCNK3Two-pore K⁺ channelChannelopathy mechanism
SMAD9Downstream of BMPR2 signaling
CAV1Caveolin-1
EIF2AK4ARPulmonary veno-occlusive disease / pulmonary capillary hemangiomatosis: distinct entity that resembles PAH but has different prognosis and treatment caution
TBX4Transcription factorChildhood-onset PAH, often syndromic

Anticipation has been described in some BMPR2 kindreds (younger age at diagnosis in successive generations); mechanism not fully understood, possibly ascertainment bias plus modifier effects.

BMPR2 encodes a receptor of the TGF-β superfamily that is highly expressed on the pulmonary vascular endothelium. There it pairs with ALK1 (encoded by ACVRL1) and uses endoglin (ENG) as a coreceptor to answer the circulating ligands BMP9 (encoded by GDF2) and BMP10, and it signals through Smad1, Smad5, and Smad8 (encoded by SMAD9). BMP9 keeps the vessel quiet: it protects endothelial cells from apoptosis and excess proliferation. Most BMPR2 variants are loss of function, some dominant negative. Losing the signal favors endothelial dysfunction, and smooth muscle cells with BMPR2 variants overgrow because they resist the growth-suppressing effect of BMPs. That most heritable PAH genes sit in this one pathway marks the endothelial cell as the likely starting point, and explains the overlap with hereditary hemorrhagic telangiectasia (ACVRL1, ENG). Other genes act elsewhere: KCNK3 variants reduce the conductance of a potassium channel that sets pulmonary vascular tone, and TBX4 variants suggest a developmental lung disease in children. The genotype bears on treatment and prognosis: disease with a BMPR2 or ACVRL1 variant presents younger, with worse hemodynamics, a very low chance of acute vasoreactivity, and shorter survival.

  • Hemodynamic definition (2022 ESC/ERS guidelines): pre-capillary PH = mPAP ≥20 mmHg, PVR ≥2 WU, PAWP ≤15 mmHg
  • Progressive dyspnea on exertion, fatigue, exertional syncope (low cardiac output during exercise)
  • Right heart failure: hepatomegaly, ascites, peripheral edema, JVD
  • Loud P2, RV heave, tricuspid regurgitation murmur on exam
  • ECG: right axis deviation, RV hypertrophy, RA enlargement
  • CXR: enlarged central pulmonary arteries with peripheral pruning, RV enlargement
  • Echo: estimated PASP, RV dilation/dysfunction, paradoxical septal motion
  • Right heart catheterization is required for diagnosis: also rules out left heart disease
  • Right heart catheterization is the diagnostic gold standard: confirms pre-capillary PH (mPAP ≥20 mmHg, PVR ≥2 WU, PAWP ≤15 mmHg) and excludes left heart disease; vasoreactivity testing guides calcium-channel-blocker candidacy
  • Transthoracic echocardiography is the first-line screening test (estimates PASP, assesses RV size/function) and is used for surveillance of asymptomatic gene carriers
  • Workup excludes secondary causes (V/Q scan for chronic thromboembolic PH, PFTs, HRCT, autoimmune serologies) before labeling PAH as heritable/idiopathic
  • Gene panel testing (BMPR2 most common) confirms heritable PAH and enables cascade screening; HRCT and EIF2AK4 testing distinguish PVOD, which alters vasodilator safety
  • Reduced penetrance is the dominant counseling theme: most carriers will not develop disease, but the ~15-20% who do have severe morbidity/mortality
  • Female bias among affected; multifactorial; estrogen metabolism implicated
  • Cascade testing at-risk relatives: identifies carriers for surveillance (annual echo + symptom review starting in adolescence)
  • Pregnancy is contraindicated in known PAH: historically cited maternal mortality ~30-50% (contemporary specialized-center series report lower, roughly 10–25%, but pregnancy remains contraindicated); preconception counseling for known carriers should address this even before symptoms develop
  • PVOD (EIF2AK4) caution: PAH-specific vasodilators can precipitate fatal pulmonary edema in PVOD; distinguishing PAH from PVOD before vasodilator therapy is critical (HRCT findings: septal lines, ground-glass, mediastinal LAD)
  • PAH-specific therapy (combination based on risk stratification):
    • Endothelin receptor antagonists (bosentan, ambrisentan, macitentan)
    • PDE5 inhibitors (sildenafil, tadalafil) or sGC stimulator (riociguat)
    • Prostacyclin pathway agents (epoprostenol, treprostinil, selexipag)
  • Diuretics for right heart failure
  • Anticoagulation in select cases
  • Lung (or heart-lung) transplantation for end-stage disease
  • Annual screening echo for known asymptomatic gene carriers

Reference Links